David Moliterno, MD, Professor of Medicine

Dr. David J. Moliterno is Professor of Medicine in the Division of Cardiovascular Medicine at the University of Kentucky. Dr. Moliterno previously served as Chief of the Division of Cardiovascular Medicine for 8 years, and for a 10-year term, he served as the Chairman of Internal Medicine and Vice-Dean for Clinical Affairs. Clinically, Dr. Moliterno was a busy staff practitioner for 10 years at the Cleveland Clinic, before joining the University of Kentucky.
Dr. Moliterno is a fellow of the American College of Cardiology, European Society of Cardiology, Society of Coronary Angiography and Interventions, and the American Heart Association. He has served on the Cardiorenal Drug Advisory Panel for the U.S. Food and Drug Administration (FDA) and the Circulatory System Devices Panel. He has been a visiting professor or invited lecturer in more than 30 countries. He is the author or coauthor of over 400 scientific publications (h-index >50) and editor of 10 textbooks. He has been the primary author of manuscripts in Annals of Internal Medicine, Circulation, JACC, JAMA, Lancet, BMJ, and the New England Journal of Medicine.
As a clinical researcher, Dr. Moliterno has been a leader for numerous multinational investigational studies in cardiovascular medicine as principal investigator, international steering committee member, or DSMB lead. Collectively, these studies have involved nearly $2 billion in clinical trial research. Over the past several years, Dr. Moliterno has served as the Editor-in-Chief for the Journal of the American College of Cardiology—Cardiovascular Interventions. Globally, this is the top-ranked journal in its subspecialty area with distribution in 54 countries.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Janssen PharmaceuticalsTopic:DSMB member for Factor XIa studyDate added:02/18/2026Date updated:02/18/2026Relationship end date:02/18/2028
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ProlocorTopic:Advisor for diagnostic test developmentDate added:02/18/2026Date updated:02/18/2026Relationship end date:02/18/2028

Facebook
X
LinkedIn
Forward